Epalrestat and Methylcobalamin are the fixed drug combination approved by the CDSCO for the treatment of Diabetic Neuropathy. A simple and sensitive spectrophotometric method has been developed for Epalrestat and Methylcobalamin in a combined pharmaceutical dosage form. Linearity range was observed in the concentration range of 5-25 μg/ml for Epalrestat and 10-50 μg/ml for Methylcobalamin. The method involved Q-absorption analysis based on the measurement of absorbance at two wavelengths, i.e. λmax of Methylcobalamin (351.50 nm) and Iso-absorptive point of both drugs (267.50 nm). The method was validated statistically and recovery study was performed to confirm the accuracy of the method. The method was found to be rapid, simple, accurate and precise.
Loading....